Clinical Benefit of Long-Term Disease Control with Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients

Background: We retrospectively analysed relapsed/refractory MM (RRMM) patients treated with pomalidomide and dexamethasone (PomaD) either in real life, or previously enrolled in an interventional (STRATUS, MM-010) or currently enrolled in an observational study (MM-015) to provide further insights o...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:J Clin Med
Main Authors: Parisi, Marina Silvia, Leotta, Salvatore, Romano, Alessandra, Del Fabro, Vittorio, Martino, Enrica Antonia, Calafiore, Valeria, Giubbolini, Rachele, Markovic, Uros, Leotta, Valerio, Di Giorgio, Mary Ann, Tibullo, Daniele, Di Raimondo, Francesco, Conticello, Concetta
Format: Artigo
Jezik:Inglês
Izdano: MDPI 2019
Teme:
Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC6832641/
https://ncbi.nlm.nih.gov/pubmed/31623097
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/jcm8101695
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki